1. Introduction

The Artificial Placenta Doctrine of Accountability is a proposed legal and ethical framework for determining who should be responsible when artificial placenta technology causes, contributes to, or fails to prevent injury, developmental harm, or death to a developing human being.

It is important to clarify that this is not yet a formally established legal doctrine recognised by courts under that name. It is an analytical framework that can be developed from existing principles of medical negligence, product liability, informed consent, research ethics, constitutional rights, and healthcare regulation.

Artificial placenta technology is commonly discussed under the broader term Artificial Amnion and Placenta Technology (AAPT) or artificial womb technology. It aims to support a fetus delivered extremely prematurely by providing an external fluid environment and systems that help maintain fetal physiology. Research has demonstrated proof of concept in animal models, but its translation into human clinical treatment raises unresolved legal questions.

PubMed Central (PMC)

+1

The central question is:

When a developing human being depends on an artificial placenta for survival, who is legally accountable if the technology, its operator, its manufacturer, or a healthcare institution fails?

The answer depends on the applicable jurisdiction, the circumstances of treatment, the standard of care, the cause of the harm, and the legal status of the developing entity.

2. Meaning and scope of the doctrine

The proposed doctrine brings together six major principles.

1. Clinical accountability

Physicians and clinical teams must act according to the applicable professional standard, monitor the developing entity, recognise complications, and respond appropriately to emergencies.

2. Manufacturer accountability

Manufacturers may be responsible for defective devices, unsafe designs, inadequate instructions, manufacturing errors, and failures to communicate known risks.

3. Institutional accountability

Hospitals and research institutions must establish appropriate staffing, training, maintenance, emergency procedures, infection control, and incident-reporting systems.

4. Regulatory accountability

Regulators must exercise their statutory powers appropriately in evaluating safety, approving clinical investigations where required, monitoring adverse events, and enforcing applicable rules.

5. Parental rights and informed consent

Parents or legally authorised representatives should receive understandable information about foreseeable risks, uncertainties, alternatives, and the research or treatment status of the device, subject to applicable law.

6. Remedies and compensation

The legal system should provide appropriate mechanisms to investigate harm, preserve evidence, determine responsibility, and award remedies where liability is established.

These principles are derived from existing legal doctrines; they should not be mistaken for a single statute or binding judicial test specifically governing artificial placenta systems.

3. Essential legal principles of accountability

A. Duty of care and medical negligence

The first question is whether a doctor, hospital, or other responsible party owed a legal duty of care and breached that duty, causing legally recognised harm.

In artificial placenta treatment, relevant duties may include:

Assessing whether the developing entity is suitable for the intervention.

Using the device in accordance with accepted clinical and safety protocols.

Monitoring oxygenation, circulation, temperature, infection risks, and other relevant physiological parameters.

Responding promptly to alarms, equipment failures, or signs of deterioration.

Arranging appropriate alternative treatment where clinically possible.

These are examples of potential duties, not a universal checklist prescribed by an existing artificial-placenta statute.

Indian case law: Jacob Mathew v. State of Punjab (2005) 6 SCC 1.

The Supreme Court of India explained the essential elements of negligence as duty, breach, and resulting damage. It also distinguished civil negligence from criminal negligence, emphasising that criminal liability for a medical professional requires a substantially higher degree of negligence than ordinary civil liability.

Indian Kanoon

Application: If a hospital uses an artificial placenta without adequate monitoring or fails to respond to a foreseeable device malfunction, civil liability may arise if the relevant duty, breach, causation, and damage are proved. A poor clinical outcome alone does not establish negligence. Criminal liability requires the applicable criminal-law elements to be independently established.

B. Informed consent and reproductive autonomy

Artificial placenta treatment may involve difficult decisions concerning experimental interventions, risks of extreme prematurity, alternative neonatal care, and the consequences of transferring a developing entity from the uterus to an external gestational system.

Valid consent requires more than obtaining a signature. The responsible medical team should explain material risks, expected benefits, reasonable alternatives, uncertainties, and the nature of the intervention in language appropriate to the decision-maker.

Indian case law: Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1.

The Supreme Court addressed the principles governing valid medical consent, including the need for adequate information and the limits of consent to one procedure when a materially different procedure is undertaken. The Court's principles are relevant to considering consent for complex artificial placenta interventions.

Sci API

+1

Application: A hospital could face legal scrutiny if it misrepresents an experimental artificial placenta as established treatment or performs a materially different intervention without legally adequate authorisation, except where a recognised legal exception applies.

Where the developing entity cannot consent, the authority of parents or other representatives and the applicable best-interests standard must be considered. Parental permission does not automatically make an unsafe or unlawful intervention acceptable.

C. Manufacturer and product liability

Artificial placenta systems may combine pumps or circulation systems, sensors, fluid management, monitoring software, alarms, sterile components, and life-support infrastructure. A failure in any critical component may create serious risks.

Potential product-related claims include:

Design defect: the system contains an unreasonably dangerous design under the applicable legal test.

Manufacturing defect: a particular device departs from its intended specifications.

Failure to warn: relevant risks, limitations, contraindications, or operating requirements were not adequately communicated.

Software or control-system defect: an algorithm, sensor, or alarm fails in a manner attributable to a legally actionable defect.

Post-market failure: the manufacturer does not take legally required action after learning of serious safety problems.

The existence of a malfunction does not automatically establish liability. The claimant must satisfy the relevant statutory or common-law requirements, including causation where required.

In India, product-liability provisions under the Consumer Protection Act, 2019, may be relevant depending on the product, parties, claim, and statutory conditions. Medical negligence claims may also arise independently.

D. Hospital and institutional accountability

An artificial placenta may require continuous supervision and coordinated work among neonatologists, surgeons, nurses, biomedical engineers, and other specialists.

Institutional failures can include:

Inadequate staffing or training.

Failure to maintain or inspect equipment.

Poor infection-control practices.

Inadequate emergency backup systems.

Deficient clinical documentation.

Failure to investigate recurring alarms or adverse events.

In Jacob Mathew, the Supreme Court recognised that failures in hospital systems, such as the non-availability of essential oxygen equipment, may raise questions of institutional responsibility distinct from the criminal liability of an individual doctor.

Indian Kanoon

Application: If an artificial placenta fails because a hospital did not maintain required backup equipment, the institution's responsibility must be examined separately from whether an individual clinician acted negligently.

E. Regulatory and research accountability

Before an artificial placenta is used in human clinical practice, regulators and research ethics bodies may need to evaluate device safety, study design, participant protection, monitoring arrangements, and reporting obligations under the applicable jurisdiction.

Accountability can arise at several levels:

Researchers must comply with approved protocols and research-ethics requirements.

Sponsors must meet applicable safety-monitoring and reporting obligations.

Manufacturers must comply with relevant medical-device requirements.

Hospitals must ensure appropriate authorisation, training, and clinical governance.

Regulators must act within their statutory authority and follow applicable procedural requirements.

Regulatory approval does not necessarily eliminate civil liability, and the absence of proven negligence does not mean that a system-level safety investigation is unnecessary.

4. Important case laws and their relevance

The following cases are relevant by analogy. None of these decisions establishes a binding, artificial-placenta-specific doctrine of accountability.

The Indian authorities above supply established legal principles that could be applied to future artificial placenta disputes. They do not decide questions such as whether a fetus maintained in an artificial gestational environment is legally born alive, or how death in such a system should be classified.

For that unresolved issue, the 2024 article Death and the Artificial Placenta examines how existing law in England and Wales may struggle to classify death where a developing entity is sustained by artificial placenta technology.

Oxford Academic

+1

5. The artificial placenta accountability test

A proposed accountability framework can be structured as a sequence of legal questions.

Step 1 — Identify the harm

Injury, infection, developmental impairment, device failure, or death

Step 2 — Identify the duty-holder

Clinician, hospital, manufacturer, researcher, sponsor, or regulator

Step 3 — Determine the breach

Was a legal duty, applicable safety requirement, or professional standard violated?

Step 4 — Establish causation

Did the breach cause or materially contribute to the harm under the applicable legal test?

Step 5 — Determine liability and remedy

Compensation, regulatory action, professional discipline, or criminal proceedings where legally justified

This framework is a proposed analytical tool, not a new judicially established test. Different claims may require different elements, burdens of proof, and remedies.

6. Hypothetical case study

Consider a hospital treating an extremely premature infant using an artificial placenta system in an authorised clinical study.

During treatment, a circulation sensor provides repeated abnormal readings. The monitoring system fails to alert the clinical team because of a software defect. Staff do not recognise the deterioration promptly, and the infant suffers serious injury.

The legal analysis would consider several possible defendants.

The injury does not automatically establish that every party is liable. An independent investigation would need to establish what occurred, which duties applied, whether they were breached, and how the failures contributed to the outcome.

Where several failures contribute to the same injury, the law of the relevant jurisdiction determines whether liability is apportioned, joint, several, or otherwise allocated.

7. Artificial placenta accountability in India

For an Indian legal analysis, the principal legal sources would include the following.

1. Constitution of India

Article 21 protects life and personal liberty. It may inform arguments concerning protection of life, healthcare, bodily integrity, and lawful medical decision-making. The precise application to a developing entity maintained in an artificial placenta remains unsettled.

2. Consumer Protection Act, 2019

The Act may provide remedies for qualifying deficiencies in healthcare services and product-related defects. Whether a particular claim falls within its scope depends on the facts and applicable law.

3. Bharatiya Nyaya Sanhita, 2023

Where a death or injury is alleged to result from criminally negligent conduct, the applicable provisions of the BNS and the relevant evidentiary requirements must be considered. The distinction between civil negligence and criminal negligence remains important; criminal guilt cannot be inferred merely from an unsuccessful treatment.

4. Medical-device regulation

The Medical Devices Rules, 2017, and the Drugs and Cosmetics Act, 1940, as applicable, are relevant starting points for analysing device classification, regulatory authorisation, quality requirements, and compliance. The specific classification and authorisation pathway for a future artificial placenta system would need to be determined rather than assumed.

5. Clinical research and institutional ethics

Where the technology is investigational, applicable research requirements, ethics committee oversight, participant protections, and reporting obligations must be examined. The exact requirements depend on the nature of the study and the legal framework governing it.

These sources do not, individually or collectively, establish a complete statutory artificial placenta accountability regime.

8. Unresolved legal questions

The most significant challenges are not limited to equipment safety.

Legal status: Does the developing entity qualify as a live-born person, a fetus, or another legally relevant category at each stage of treatment?

Death certification: How should death be classified if an entity is sustained by an artificial placenta but never satisfies an existing legal definition of live birth?

Parental authority: Who may authorise treatment, refuse an intervention, or request withdrawal of support?

Withdrawal of support: What legal and clinical standards should govern discontinuation when continued treatment is futile or imposes disproportionate burdens?

Causation: How should courts distinguish injury caused by the device from injury associated with extreme prematurity or the underlying condition?

Long-term monitoring: Who should be responsible for developmental follow-up and the disclosure of newly discovered risks?

The legal literature identifies these issues as important unresolved questions, particularly where existing definitions of birth, death, pregnancy, and neonatal treatment do not fit artificial gestation neatly.

scholarship.kentlaw.iit.edu

+2

9. Conclusion

The Artificial Placenta Doctrine of Accountability can be understood as a proposed framework for ensuring that responsibility for harm is assessed across the entire artificial gestation system rather than automatically attributed to a single doctor or manufacturer.

Its central principles are duty of care, informed consent, product safety, institutional governance, regulatory compliance, causation, transparency, and effective remedies.

The Indian Supreme Court's decisions in Jacob Mathew, Samira Kohli, Laxman Joshi, and Spring Meadows Hospital provide important foundations for applying existing negligence and consent principles. However, none directly resolves artificial placenta-specific issues.

The principal legal challenge is to adapt established rules to a technology that may blur the boundaries between fetal care, neonatal intensive care, medical-device operation, and external gestation—while preserving safety, reproductive autonomy, scientific accountability, and the rights of those affected.